Tenderwize
Retour à la recherche

Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 366 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or framework maximum means potential volume is unknown.

Electronic submission is not allowed via the portal; requires email with QES or postal submission with scanned copy.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Pharmaceutical discount agreement for Teriparatid
  • Supply of the active substance to German statutory health insurance funds
Afficher le résumé complet

Open-House procedure by Techniker Krankenkasse and other German health insurers to conclude discount agreements (Rabattverträge) for the active substance Teriparatid. The procedure allows any eligible pharmaceutical entrepreneur to join at any time during the contract period (01.09.2025 to 31.08.2027). No exclusive rights are granted. The notice explicitly states this is not a public procurement subject to EU procurement law; legal disputes fall under social courts. No estimated value, award criteria, or detailed submission documents were provided in the structured data or XML notice.

Risques

No estimated value or framework maximum means potential volume is unknown.

Electronic submission is not allowed via the portal; requires email with QES or postal submission with scanned copy.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) per § 4 Abs. 18 AMG
  • Must have a valid marketing authorization for the medicinal product per § 21 AMG
  • Must have registered seat in Germany, EU, or EEA

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; in open-house, contracts are concluded with all eligible participants.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid

Conclusion of pharmaceutical discount agreements for Teriparatid under § 130a Abs. 8 SGB V via an open-house procedure. No negotiation, uniform terms. Contract duration max 24 months from 01.09.2025 to 31.08.2027.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Aug 2025 - Aug 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; in open-house, contracts are concluded with all eligible participants.

Date limite

Deadline Aug 30, 2027

Détails de la procédure

Date de publication
13 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
457552-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30